HMNC Brain Health raises $50M Series B to advance two depression drugs

June 15, 2026 02:00 AM EDTUpdated 06:29 AM FinancingStartups Ger­man biotech nets $50M to ad­vance two de­pres­sion drugs, in­clud­ing Spra­va­to chal­lenger Ayisha Sharma News Reporter HM­NC Brain Health has se­cured $50 mil­lion in a Se­ries B fundraise de­signed to sup­port two psy­chi­a­try pro­grams in­to mid-stage stud­ies. The fam­i­ly-owned Ger­man drug­mak­er … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER